Jane E Hartigan, PA
Physician Assistant · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · California Sports and Orthopaedic · Sutter Bay Medical Foundation
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jane E Hartigan’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$175,394
Medicare paid this office $175,394 for 359 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 206 | $50,034 | $92 |
| Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg | 65 | $42,863 | None |
| Short return visit (20+ min) | 225 | $22,816 | $69 |
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 50 | $13,937 | None |
| Return visit (30+ min) | 104 | $11,047 | $100 |
See all 19 services
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 206 | $50,034 | $92 |
| Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg | 65 | $42,863 | None |
| Short return visit (20+ min) | 225 | $22,816 | $69 |
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 50 | $13,937 | None |
| Return visit (30+ min) | 104 | $11,047 | $100 |
| Prosthetic repair of shoulder joint, total shoulder | 25 | $4,618 | $178 |
| New patient visit (30+ min) | 59 | $4,600 | $78 |
| Replacement of knee joint, both sides of knee | 24 | $3,699 | $154 |
| X-ray of shoulder, minimum of 2 views | 60 | $2,203 | $30 |
| X-ray of knee, 1-2 views | 32 | $1,508 | $31 |
| Repair of shoulder rotator cuff using an endoscope | 12 | $1,333 | $111 |
| New patient visit (45+ min) | 12 | $1,204 | $100 |
| Complete ultrasound scan of joint | 24 | $940 | $39 |
| X-ray of knee, 3 views | 24 | $812 | $32 |
| X-ray of both knees while standing | 18 | $650 | $36 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 109 | $502 | None |
| X-ray of knee, 4 or more views | 13 | $466 | $36 |
| Shaving of part of shoulder bone and repair of ligament using an endoscope | 17 | $299 | $18 |
| Harvest of graft from small bone | 24 | $262 | $11 |
Procedures Medicare counted
| Knee replacement | 11 | More than 37% of doctors who do this |
| Upper limb (arm) arthroscopy (minimally invasive joint repair) | 31 | More than 75% of doctors who do this |
Who their Medicare patients are
359 Original Medicare patients in 2024. Average age 75 · Women 62% · Also on Medicaid 4% · Health risk score 0.83. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 56% · Depression 20% · Coronary heart disease 17% · Chronic kidney disease 15% · Cancer 15% · Diabetes 14% · Atrial fibrillation 13% · Heart failure 7% · Stroke 6% · COPD 5%.
The office billed $665,647, Medicare allowed $227,911 and paid $175,394; for 42,818 services of 40 kinds; $65,783 of it was for drugs given in the office and $109,611 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 359 | 42,818 | 75 | 0.83 | $665,647 | $175,394 |
| 2023 | 676 | 33,600 | 73 | 1.35 | $741,533 | $156,940 |
| 2022 | 432 | 1,788 | 72 | 1.58 | $449,039 | $100,245 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Return visit (30+ min) | 392 | $55,197 | $82 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 134 | $28,696 | $92 |
| Short return visit (20+ min) | 234 | $19,903 | $64 |
| Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg | 24 | $16,018 | None |
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 45 | $13,420 | None |
| New patient visit (30+ min) | 36 | $3,034 | $84 |
| Replacement of knee joint, both sides of knee | 14 | $2,193 | $157 |
| Short return visit | 55 | $2,175 | $38 |
| Testing for presence of drug, by chemistry analyzers | 22 | $1,340 | $61 |
| X-ray of shoulder, minimum of 2 views | 29 | $981 | $30 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $889 | $59 |
| X-ray of knee, 3 views | 22 | $870 | $36 |
| Electronic analysis reprogramming and refill of spinal canal drug infusion pump by physician | 18 | $860 | $37 |
| X-ray of knee, 1-2 views | 16 | $823 | $30 |
| Administration of psychological or neuropsychological test by single standardized instrument via electronic platform with automated result | 281 | $610 | $1 |
| Complete ultrasound scan of joint | 14 | $602 | $40 |
| X-ray of both knees while standing | 13 | $465 | $36 |
| X-ray of knee, 4 or more views | 11 | $457 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 84 | $421 | None |
2022: 8 services
| Return visit (30+ min) | 314 | $69,264 | $94 |
| Short return visit (20+ min) | 170 | $17,755 | $66 |
| Electronic analysis reprogramming and refill of spinal canal drug infusion pump by physician | 20 | $3,563 | $71 |
| Telephone medical discussion with physician, 11-20 minutes | 31 | $2,415 | $67 |
| Testing for presence of drug, by chemistry analyzers | 27 | $1,774 | $61 |
| Short return visit | 28 | $1,266 | $42 |
| Administration of psychological or neuropsychological test by single standardized instrument via electronic platform with automated result | 249 | $609 | $1 |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $527 | $41 |
Medicaid work
$1,966 in 2023
Medicaid paid $1,966 for 171 billed services this clinician did in 2023, up to 45 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 147 | $1,774 |
| Short return visit (20+ min) | 24 | $192 |
| 2023 | 171 | 2 | 45 | $1,966 |
| 2022 | 260 | 2 | 41 | $394 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 224 | $377 |
| Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only | 36 | $17 |
Drugs they prescribed that Part D paid
$4,748
Pharmacies billed $4,748 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 27% of their Part D prescriptions (119 of 434) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
433 generic and fewer than 11 brand-name prescriptions · $4,748 in drug cost · 79 antibiotic prescriptions to 53 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Celecoxib | 98 | $3,236 | $33 |
| Oxycodone-Acetaminophen | 108 | $715 | $7 |
| Ondansetron | 80 | $267 | $3 |
| Cephalexin | 77 | $160 | $2 |
| Meloxicam | 29 | $34 | $1 |
Year by year
| 2024 | 434 | 138 | 27% (119) | None | $4,748 |
| 2023 | 903 | 325 | 45% (407) | None | $30,941 |
| 2022 | 1,724 | 330 | 59% (1,014) | 3% | $73,208 |
| 2021 | 1,280 | 341 | 60% (770) | 3% | $46,979 |
| 2020 | 1,377 | 335 | 60% (819) | 5% | $50,534 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Celecoxib | 106 | $6,555 | $62 |
| Hydrocodone-Acetaminophen | 158 | $5,634 | $36 |
| Gabapentin | 128 | $2,788 | $22 |
| Oxycodone-Acetaminophen | 105 | $2,682 | $26 |
| Lidocaine | 25 | $2,128 | $85 |
| Oxycodone | 59 | $1,489 | $25 |
| Pregabalin | 33 | $1,237 | $37 |
| Morphine Sulfate Er | 16 | $519 | $32 |
| Diclofenac | 20 | $388 | $19 |
| Cyclobenzaprine | 29 | $363 | $13 |
| Tramadol | 28 | $299 | $11 |
| Ondansetron | 32 | $245 | $8 |
| Methadone | 18 | $191 | $11 |
| Methocarbamol | 12 | $166 | $14 |
| Meloxicam | 18 | $117 | $6 |
| Ibuprofen | 15 | $92 | $6 |
| Cephalexin | 31 | $69 | $2 |
2022: 21 drugs
| Hydrocodone-Acetaminophen | 453 | $14,877 | $33 |
| Oxycontin | 14 | $7,099 | $507 |
| Oxycodone-Acetaminophen | 183 | $6,734 | $37 |
| Lidocaine | 46 | $5,996 | $130 |
| Gabapentin | 206 | $4,330 | $21 |
| Oxycodone | 165 | $4,105 | $25 |
| Celecoxib | 53 | $3,399 | $64 |
| Pregabalin | 43 | $1,752 | $41 |
| Cyclobenzaprine | 66 | $1,199 | $18 |
| Morphine Sulfate Er | 36 | $1,083 | $30 |
| Tramadol | 59 | $1,017 | $17 |
| Methadone | 74 | $877 | $12 |
| Diclofenac | 56 | $859 | $15 |
| Duloxetine | 11 | $412 | $37 |
| Methocarbamol | 34 | $394 | $12 |
| Ibuprofen | 37 | $338 | $9 |
| Baclofen | 18 | $305 | $17 |
| Tizanidine | 14 | $234 | $17 |
| Amitriptyline | 12 | $161 | $13 |
| Hydromorphone | 13 | $122 | $9 |
| Meloxicam | 32 | $52 | $2 |
2021: 18 drugs
| Hydrocodone-Acetaminophen | 313 | $10,823 | $35 |
| Oxycontin | 14 | $5,830 | $416 |
| Oxycodone-Acetaminophen | 150 | $5,309 | $35 |
| Lidocaine | 24 | $4,455 | $186 |
| Oxycodone | 147 | $3,893 | $26 |
| Gabapentin | 149 | $2,277 | $15 |
| Morphine Sulfate Er | 59 | $2,054 | $35 |
| Pregabalin | 24 | $1,350 | $56 |
| Cyclobenzaprine | 61 | $1,059 | $17 |
| Celecoxib | 26 | $1,024 | $39 |
| Diclofenac | 46 | $805 | $17 |
| Methadone | 37 | $603 | $16 |
| Morphine Sulfate | 15 | $515 | $34 |
| Methocarbamol | 21 | $304 | $14 |
| Tramadol | 21 | $221 | $11 |
| Ibuprofen | 20 | $143 | $7 |
| Tizanidine | 12 | $101 | $8 |
| Meloxicam | 31 | $91 | $3 |
2020: 23 drugs
| Oxycontin | 26 | $12,000 | $462 |
| Hydrocodone-Acetaminophen | 343 | $8,519 | $25 |
| Oxycodone-Acetaminophen | 134 | $4,607 | $34 |
| Oxycodone | 134 | $3,433 | $26 |
| Gabapentin | 147 | $2,047 | $14 |
| Diclofenac | 55 | $1,456 | $26 |
| Morphine Sulfate Er | 59 | $1,354 | $23 |
| Celecoxib | 36 | $1,130 | $31 |
| Cyclobenzaprine | 82 | $1,110 | $14 |
| Pregabalin | 27 | $1,048 | $39 |
| Lidocaine | 13 | $883 | $68 |
| Morphine Sulfate | 25 | $832 | $33 |
| Methadone | 34 | $373 | $11 |
| Tramadol | 39 | $308 | $8 |
| Duloxetine | 12 | $292 | $24 |
| Acetaminophen-Codeine | 14 | $274 | $20 |
| Baclofen | 13 | $208 | $16 |
| Tizanidine | 11 | $186 | $17 |
| Meloxicam | 39 | $184 | $5 |
| Ondansetron | 11 | $171 | $16 |
| Ibuprofen | 14 | $152 | $11 |
| Methocarbamol | 17 | $144 | $8 |
| Clonidine | 15 | $23 | $2 |
Money from drug and device companies
$41 in 2025
| 2025 | 2 | 2 | None | $41 |
| 2024 | 1 | 1 | None | $70 |
| 2023 | 3 | 20 | $3,800 | $6,601 |
| 2022 | 5 | 45 | $10,494 | $16,429 |
| 2021 | 3 | 41 | $2,946 | $3,998 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Stryker | Aequalis Perform Reversed | $25 | 1 payment
|
| Boston Scientific | General - Pain Management | $16 | 1 payment
|
See all 2 published payments
| Stryker | Meals · 2025-12-16 | Aequalis Perform Reversed | $25 |
| Boston Scientific | Meals · 2025-10-09 | General - Pain Management | $16 |
See earlier years (2024, 2023, 2022, 2021)
2024: $70
| Bioventus | Durolane | $70 | 1 payment
|
2023: $6,601
| Saluda Medical Americas | Evoke Scs | $6,516 | 18 payments
|
| Bioventus | Gelsyn-3 | $60 | 1 payment
|
| Abbott Laboratories | Proclaim | $25 | 1 payment
|
2022: $16,429
| Vertos Medical | Mild Device Kit | $8,331 | 12 payments
|
| Saluda Medical Americas | Evoke Scs | $7,667 | 21 payments
|
| Abbott Laboratories | Proclaim | $326 | 7 payments
|
| SPR Therapeutics | Sprint Pns System | $65 | 1 payment
|
| Medtronic | Synchromedii | $39 | 2 payments
|
2021: $3,998
| Vertos Medical | Mild Device Kit | $2,592 | 7 payments
|
| Abbott Laboratories | Proclaim Ipg | $1,294 | 32 payments
|
| Boston Scientific | General - Pain Management | $112 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Saluda Medical Americas, Inc. · Ecap Study · 2021 | This clinician | $234 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417594318
- Licence
- CA 57589
- Group
- California Sports and Orthopaedic · Sutter Bay Medical Foundation
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant, surgical (363AS0400X)
- Mailing address
- 416 Aviation Blvd Ste B, Santa Rosa, CA, 95403
- NPI first listed
- 2019-12-10
- NPI last updated
- 2025-09-29
- NPI record certified
- 2025-09-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2999 Regent St Ste 225, Berkeley, CA, 94705